Next & Bio to establish joint organoid research institute with Singapore Cancer Research Institute
Jul 31, 2025
|
The agreement ceremony held in Singapore was attended by Park Sang-wook, CEO of Next & Bio, NUS Professor Ashok Venkitaraman, and the Korea Startup Center (KSC).
Through a joint study, Next & Bio will secure organoids derived from various Asian cancer patients, including Chinese, Indian, and Malaysian living in Singapore. Based on this, research on new drug development and treatment response prediction will be in full swing, and a new evaluation platform will be jointly developed to replace preclinical animal testing.
The study involves a number of cancer-specialized clinicians and researchers, including Professor Ashok Venkitaraman, a world-renowned clinical scientist and chair professor at the NUS School of Medicine. Next & Bio plans to expand its precision medical evaluation technology, which was being developed in Korea, globally by putting organoid professional researchers in Singapore. In particular, it plans to strengthen its global network by promoting collaboration with large pharmaceutical companies in Singapore.
Park Sang-wook, CEO of Next&Bio, said, `This joint research is meaningful in that we work with world-class cancer research experts to establish a high-quality R&D system, which will be an important milestone for Next&Bio's global expansion,' adding, `We will contribute to increasing the success rate of new drug development through cooperation with several global pharmaceutical companies based in Singapore.'
This article was translated by Naver AI translator.
